drugset / Trial / NCT01199978
Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma
Phase 2
Active not recruiting
30 enrolled
Massachusetts General Hospital
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
In this research study we are looking at another type of radiation called proton radiation which is known to spare surrounding normal tissues from radiation. The proton radiation will be delivered using fractionated stereotactic radiotherapy (FSRT) to improve localization of the small tumor target. Proton radiation delivers minimal radiation beyond the area of the tumor. This may reduce side effects that patients would normally experience with conventional radiation therapy. In this research study, we are looking to determine the effects of fractionated proton radiotherapy on long-term hearing preservation and controlling tumor growth.
Timeline
- Start
- 2011-03-08
- Primary completion
- 2026-11
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Losartan | Other / unclassified | 25 mg | Oral |
| Background | Losartan | Other / unclassified | 50 mg | Oral |